OUR NAME

Altough seemingly abstract at first, our name makes total sense and subsumes our work, our self-understanding and our values.

cell noun

a small usually microscopic mass of protoplasm bounded externally by a semipermeable membrane, usually including one or more nuclei and various other organelles with their products, capable alone or interacting with other cells of performing all the fundamental functions of life, and forming the smallest structural unit of living matter capable of functioning independently

phenom noun [C] US slang

someone or something extremely successful, especially someone young in sports who achieves a lot very quickly.

-ics noun suffix

one having the character or nature of; one belonging to or associated with; one exhibiting or affected by; one that produces

Combining Christian's and Reinhold's scientific background with Quirin's expertise in the business world, CELLphenomics translates this knowledge to contribute to the fight against cancer by developing innovative patient-derived cell culture models.   

As is sports, in science certain virtues decide about success:

1

Goals

We define our goals with our customers

2

Planning and Preparation

Good planning and preparation of experiments is crucial

3

Multitasking

Combining ideas, experiments and data to refine the results as you go.

4

Hard work

Experiments are not always 9 to 5 Monday through Friday

5

Mental Strength

6

Team building

7

Sportsmanship

8

Have an idol

Our Mission

CELLphenomics is a state-of-the-art in vitro service provider aimed at offering high-quality, reasonable priced cell culture models complementing classical in vivo assays using patient-derived 3D cell cultures. We view ourselves as partners with our customers, our employees, our scientific community and our environment. Our mission is to help the biotech and pharma industries create innovative testings of novel anti-cancer drugs. We aim to become a recognized brand name in the field of preclinical testing, capitalizing on the sustained interest in alternatives to animal testing. Our goal is satisfied customers, moderate growth, annual profitability and maintaining our sense of humor.

EXECUTIVE TEAM

Dr. Christian Regenbrecht

shareholder & ceo

MAIL TO

 

Christian has studied biology and philosophy at the University of Bonn. In 2005 he did his first postdoc with Hans Lehrach at the Max Planck Institute for Molecular Genomics in Berlin. In 2010 his group moved to the Institute for Pathology at the Charité - Universitätsmedizin Berlin focussing on improved patient-derived in vitro models. During his time at the Charité he was appointed head of the core-facility for functional genomics of the Charité. Within the IMI initiative Oncotrack Christian was the the academic lead of the work package in vitro models & cancer stem cells.

In 2012 he, together with SAP was awarded with the Innovation award of the states Berlin and Brandenburg for his work on the Oncolyzer, a mobile-device app that allows to analyze clinical records of cancer-patients in real-time.

Since May 2017 he is speaker and member of the advisory committee for Berlin's "Pharma Solutions" ZIM cluster.

Christian is currently working on his habilitation and serves as reviewer for various peer-reviewed journals including PloS and Nature.

Christian is member of distinguished national and international scientific societies, including the New York Academy of Sciences (NYAS), the American Association for Cancer Research (AACR), the European Association for Cancer Research (EACR), the Connective Tissue Oncology Society (ctos), the German Cancer Society (DKG) and Berlin's Cancer Society (BKG).

Theresa M. Thole, Joern Toedling, [...], Christian RA Regenbrecht, Annette Künkele, Marco Lodrini, Angelika Eggert, Hedwig E. Deubzer. Reflection of neuroblastoma intratumor heterogeneity in the new OHC‐NB1 disease model. International Journal of Cancer. 2019 July 15

Schumacher D, Andrieux G, Boehnke K, Keil M, Silvestri A, Silvestrov M, Keilholz U, Haybaeck J, Erdmann G, Sachse C, Templin M, Hoffmann J, Boerries M, Schäfer R, Regenbrecht CRA. Heterogeneous pathway activation and drug response modelled in colorectal-tumor-derived 3D cultures. PLoS Genetics. 2019 March 29

Gantenbein N, Bernhart E, Anders I, Golob-Schwarzl N, Krassnig S, Wodlej C, Brcic L, Lindenmann J, Fink-Neuboeck N, Gollowitsch F, Stacher-Priehse E, Asslaber M, Gogg-Kamerer M, Rolff J, Hoffmann J, Silvestri A, Regenbrecht C, Reinhard C, Pehserl AM, Pichler M, Sokolova O, Naumann M, Mitterer V, Pertschy B, Bergler H, Popper H, Sattler W, Haybaeck J. Influence of eukaryotic translation initiation factor 6 on non-small cell lung cancer development and progression. Eur J Cancer. Epub 2018 Aug 1

Gambara G, Gaebler M, Keilholz U, Regenbrecht CRA, Silvestri A. From Chemotherapy to Combined Targeted Therapeutics: In Vitro and in Vivo Models to Decipher Intra-tumor Heterogeneity. Front Pharmacol. 2018 Feb 14

Joseph L Regan, Dirk Schumacher, Stephanie Staudte, Andreas Steffen, Johannes
Haybaeck, Ulrich Keilholz, Caroline Schweiger, Nicole Golob-Schwarzl, Dominik Mumberg, David Henderson, Hans Lehrach, Christian RA Regenbrecht, Reinhold Schäfer, Martin Lange: Non-Canonical Hedgehog signaling is a positive regulator of the WNT pathway and is required for the survival of colon cancer stem cells. Cell Reports 2017 Dec 5

Manuela Gaebler, Alessandra Silvestri, Johannes Haybaeck, Peter Reichardt, Caitlin D. Lowery, Louis F. Stancato, Gabriele Zybarth and Christian R. A. Regenbrecht. Three-Dimensional Patient-Derived In Vitro Sarcoma Models: Promising Tools for Improving Clinical Tumor Management. Front Onc. 2017 Sep 11

Nicole Golob-Schwarzl, Caroline Schweiger, Carina Koller,[…], Christian RA Regenbrecht, […], Johannes Haybaeck. Separation of low and high grade colon and rectum carcinoma by eukaryotic translation initiation factors 1, 5 and 6. Oncotarget. 2017 Sep.

Schütte M, Risch T, Abdavi-Azar N, Boehnke K, Schumacher D […], Regenbrecht CRA et al. Molecular dissection of colorectal cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitors. Nat Commun. 2017 Feb 10;8:14262. PubMed PMID: 28186126.

Redmer T, Walz I, Klinger B, Khouja S, Welte Y, Schäfer R, Regenbrecht C. The role of the cancer stem cell marker CD271 in DNA damage response and drug resistance of melanoma cells. Oncogenesis. 2017 Jan 23;6(1):e291. doi: 10.1038/oncsis.2016.88. PMID: 28112719

Boehnke K, Iversen PW, Schumacher D, Lallena MJ, Haro R, Amat J, Haybaeck J, Liebs S, Lange M, Schäfer R, Regenbrecht CR, Reinhard C, Velasco JA. Assay Establishment and Validation of a High-Throughput Screening Platform for Three-Dimensional Patient-Derived Colon Cancer Organoid Cultures. Journal of biomolecular screening. 2016; 21(9):931-41. PubMed [journal] PMID: 27233291, PMCID: PMC5030729

Wruck W, Kashofer K, Rehman S, Daskalaki A, Berg D, Gralka E, Jozefczuk J, Drews K, Pandey V, Regenbrecht C RA, Wierling C, Turano P, Korf U, Zatloukal K, Lehrach H, Westerhoff HV, Adjaye J. Multi-omic profiles of human non-alcoholic fatty liver disease tissue highlight heterogenic phenotypes. Sci Data. 2015 Dec 8;2:150068. doi: 10.1038/sdata.2015.68. PubMed PMID: 26646939; PubMed Central PMCID: PMC4672680.

Soysal SD, Kilic IB, Regenbrecht C RA, Schneider S, Muenst S, Kilic N, Güth U, Dietel M, Terracciano LM, Kilic E. Status of estrogen receptor 1 (ESR1) gene in mastopathy predicts subsequent development of breast cancer. Breast Cancer Res Treat. 2015 Jun;151(3):709-15. doi: 10.1007/s10549-015-3427-y. Epub 2015 May 16. PubMed PMID: 25981900.

Redmer T, Welte Y, Behrens D, Fichtner I, Przybilla D, Wruck W, Yaspo ML, Lehrach H, Schäfer R, Regenbrecht CR. The nerve growth factor receptor CD271 is crucial to maintain tumorigenicity and stem-like properties of melanoma cells. PloS one. 2014; 9(5):e92596. PubMed [journal] PMID: 24799129, PMCID: PMC4010406

Henderson D, Ogilvie LA, Hoyle N, Keilholz U, Lange B, Lehrach [...] Regenbrecht C RA. Personalized medicine approaches for colon cancer driven by genomics and systems biology: OncoTrack. Biotechnol J. 2014 Sep;9(9):1104-14. doi:10.1002/biot.201400109. Epub 2014 Jul 29. PubMed PMID: 25074435.

Banning A, Regenbrecht C RA, Tikkanen R. Increased activity of mitogen activatedprotein kinase pathway in flotillin-2 knockout mouse model. Cell Signal. 2014 Feb;26(2):198-207. doi: 10.1016/j.cellsig.2013.11.001. Epub 2013 Nov 9. PubMedPMID: 24216609.

Wruck W, Peuker M, Regenbrecht CR. Data management strategies formultinational large-scale systems biology projects. Brief Bioinform. 2014 Jan;15(1):65-78. doi: 10.1093/bib/bbs064. Epub 2012 Oct 9. Review. PubMed PMID:23047157; PubMed Central PMCID: PMC3896927.

Redmer T, Welte Y, Behrens D, Fichtner I, Przybilla D, Wruck W, Yaspo ML,Lehrach H, Schäfer R, Regenbrecht C RA. The nerve growth factor receptor CD271 iscrucial to maintain tumorigenicity and stem-like properties of melanoma cells.PLoS One. 2014 May 5;9(5):e92596. doi: 10.1371/journal.pone.0092596. eCollection 2014. PubMed PMID: 24799129; PubMed Central PMCID: PMC4010406.

Busse A, Letsch A, Fusi A, Nonnenmacher A, Stather D, Ochsenreither S, Regenbrecht C RA, Keilholz U. Characterization of small spheres derived fromvarious solid tumor cell lines: are they suitable targets for T cells? Clin ExpMetastasis. 2013 Aug;30(6):781-91. doi: 10.1007/s10585-013-9578-5. Epub 2013 Mar 22. PubMed PMID: 23519726.

Welte Y, Davies C, Schäfer R, Regenbrecht CR. Patient derived cell culture andisolation of CD133⁺ putative cancer stem cells from melanoma. J Vis Exp. 2013 Mar13;(73):e50200. doi: 10.3791/50200. PubMed PMID: 23525090.

Jozefczuk J, Kashofer K, Ummanni R, Henjes F, Rehman S, Geenen S, Wruck W, Regenbrecht C, Daskalaki A, Wierling C, Turano P, Bertini I, Korf U, Zatloukal K,Westerhoff HV, Lehrach H, Adjaye J. A Systems Biology Approach to Deciphering theEtiology of Steatosis Employing Patient-Derived Dermal Fibroblasts and iPS Cells.Front Physiol. 2012 Sep 3;3:339. doi: 10.3389/fphys.2012.00339. eCollection 2012.PubMed PMID: 22969728; PubMed Central PMCID: PMC3432516.

Duenisch P, Reichart R, Mueller U, Brodhun M, Bjerkvig R, Romeike B, Walter J, Herbold C, Regenbrecht CR, Kalff R, Kuhn SA. Neural cell adhesion moleculeisoform 140 declines with rise of WHO grade in human gliomas and serves asindicator for the invasion zone of multiform glioblastomas and brain metastases. J Cancer Res Clin Oncol. 2011 Mar;137(3):399-414. doi: 10.1007/s00432-010-0888-6.Epub 2010 May 4. PubMed PMID: 20440511.

Welte Y, Adjaye J, Lehrach HR, Regenbrecht CR. Cancer stem cells in solidtumors: elusive or illusive? Cell Commun Signal. 2010 May 11;8(1):6. doi:10.1186/1478-811X-8-6. PubMed PMID: 20459772; PubMed Central PMCID: PMC2880310.

Brink TC, Regenbrecht C, Demetrius L, Lehrach H, Adjaye J. Activation of theimmune response is a key feature of aging in mice. Biogerontology. 2009Dec;10(6):721-34. doi: 10.1007/s10522-009-9219-1. PubMed PMID: 19255868; PubMedCentral PMCID: PMC2778679.

Kuhn SA, Mueller U, Hanisch UK, Regenbrecht CR, Schoenwald I, Brodhun M,Kosmehl H, Ewald C, Kalff R, Reichart R. Glioblastoma cells express functionalcell membrane receptors activated by daily used medical drugs. J Cancer Res Clin Oncol. 2009 Dec;135(12):1729-45. doi: 10.1007/s00432-009-0620-6. Epub 2009 Jun19. PubMed PMID: 19543745; PubMed Central PMCID: PMC2847174.

Frank S, Kuhn SA, Brodhun M, Mueller U, Romeike B, Kosmehl H, Regenbrecht CR, Ewald C, Reichart R, Kalff R. Metastatic glioblastoma cells use common pathwaysvia blood and lymphatic vessels. Neurol Neurochir Pol. 2009 Mar-Apr;43(2):183-90.PubMed PMID: 19484696.

Regenbrecht CR, Lehrach H, Adjaye J. Stemming cancer: functional genomics of cancer stem cells in solid tumors. Stem Cell Rev. 2008 Dec;4(4):319-28. doi:10.1007/s12015-008-9034-0. Review. PubMed PMID: 18561035; PubMed Central PMCID:PMC2758383.

Regenbrecht CR, Jung M, Lehrach H, Adjaye J. The molecular basis ofgenistein-induced mitotic arrest and exit of self-renewal in embryonal carcinoma and primary cancer cell lines. BMC Med Genomics. 2008 Oct 10;1:49. doi:10.1186/1755-8794-1-49. PubMed PMID: 18847459; PubMed Central PMCID: PMC2577110.


 

Quirin Graf Adelmann v. A.

shareholder & ceo

MAIL TO

Quirin Graf Adelmann was born in Munich and grew up bilingual, spending his youth in both Germany and France. He pursued a law degree at Humboldt Universität Berlin and completed his studies with the Staatsexamen (government-recognized exam). During his studies he founded the soccer club “FC Karlshorst 1995 e.V.” with 22 youth teams and close to 700 members.

Graf Adelmann went on as authorized representative and finally CEO of Herbst Motorsport, the largest car parts dealer (retail and distribution) in Northern Germany. He restructured the company, optimized processes, acquired new customers and increased profitability significantly.

From 2008, Graf Adelmann focused on real estate when he became the CEO of German operations for a London-based family investment office. Despite the financial crisis, Graf Adelmann successfully developed a new office building in Frankfurt in prime location, a TV production company in Köln and transformed an office building in Berlin Mitte into a large-scale Hotel (>120.000 guest-nights per year). He developed and invested own capital in Berlin residential projects such as "Floragärten", "Komponistengärten" and "Leo Urban Living" (combined 543 units, 44.000 sqm net residential space).

Graf Adelmann also participates in and leads many additional endeavors in the fields of culture, healthcare and FinTech startups. His portfolio includes the famous DDR Museum Berlin, the multimedia exhibition nineties berlin, a Berlin-based nursing service, Polyteia (big data for smart city) and Arttraktiv (24/7 rehearsal rooms for 1.000 musicians).

Currently Quirin serves in EU's PRECODE-Project on the board for IP, Dissemination & Exploitation

Quirin Graf Adelmann, Michael Rassinger: Evaluation, purchase and optimization of companies

Quirin Graf Adelmann, Michael Rassinger: Referral marketing in business practice

DDR Museum Guide – a companion to the permanent exhibition (Publisher), DDR Museum Verlag GmbH, 2018

Quirin Graf Adelmann: Perspectives of Freedom, DDR Museum Verlag GmbH, 2018 (out of print)

 

In preparation:

DDR in Objekten, 3 Volumes

 

Interviews, Comments:

Im Kino läuft der Skateboard-Film "Mid90s", ins Fernsehen kehrt die Serie "Beverly Hills 90210" zurück, und am Wochenende gibt es Partys mit Captain Jack: Die 90er-Jahre scheinen gerade wieder sehr präsent. Warum eigentlich? Die 90er-Jahre sind zurück. Berliner Morgenpost, 2019.

Retro-Freunde aufgepasst: Die 1990er-Jahre sind zurück. "Wir leben in Zeiten der Retrotopia, weil uns momentan eine zukunftsfähige Vision fehlt", sagt Zukunftsforscher Tristan Horx. Er glaubt, dass das nicht die letzte Retro-Welle ist: "Mit den 70ern war es genauso." Skateboards, Bauchfrei und Nirvana: Warum uns die 90er-Jahre so faszinieren. Südkurier, 2019.

Just as a visitor to New York might be disappointed to find a high-end clothing store where the notorious nightclub CBGB once stood, or wonder why it’s so hard to get a cheap room at the Chelsea Hotel, visitors to Berlin today will find that things have changed since the city’s hip heyday — the years immediately after the 1989 fall of the Berlin Wall. Looking Back to the ’90s, When Berlin Was the Height of Cool. New York Times, 2018.

"Wer sich an die Achtziger erinnern kann, hat sie nicht miterlebt." Fand zumindest Falco – und das gilt auch für das Berlin der Neunziger. Dabei wäre angesichts der beginnenden Aufarbeitung der Neunzigerjahre ein gutes Gedächtnis schon wichtig. Immerhin einen Crashkurs in Sachen Zeitgeschichte bietet jetzt die bis Ende Februar 2019 laufende Multimedia-Ausstellung „Nineties Berlin“ in der Alten Münze am Molkenmarkt. HipHop, Hausbesetzer, Helmut Kohl: Auf den Spuren von Berlins wilden Neunzigern. Berliner Zeitung, 2018.

Unten Klassik, oben Punk, dazwischen elektronische Musik, Techno und Hip-Hop. Die Proberäume in dem Marzahner Hochhaus an der Beilsteiner Straße sind aufgeteilt wie in einem gut sortierten Plattenregal. Proberaum im Plattenbau: Wo Musiker endlich ungestört Krach machen können. Berliner Zeitung, 2018.

Ein Konzept stellt immer eine Idee oder Initiative unter dem Einsatz von Menschen in den Vordergrund. Das Land Berlin – also der Staat – sollte sich im Bereich Tourismus zuallererst damit beschäftigen, die Infrastruktur zu verbessern und ein möglichst hohes Maß an Sicherheit für Touristen und Berliner zu schaffen. Es gilt, Berlins Image als "Stadt der Freiheit" weiter nach außen zu tragen und bewusst den Vergleich mit anderen Städten zu wagen, um europaweit und global attraktiv zu bleiben. Goodbye, Stadt der Freiheit. Intoura, 2018.

Maxine Sil'vestrov, MSc

Chief Operating Officer and PD3D® expert

MAIL TO

Maxine Silvestrov has studied Biotechnology and Molecular Life Science in Braunschweig and Berlin. She obtained her Bachelor of Science majoring in cell biology at the Technical University of Braunschweig. In 2012, Maxine finished her Master of Science at Humboldt University of Berlin. She accomplished her master thesis in the department of experimental pharmacology in the group of Dr. Iduna Fichtner at the Max Delbrück Center for Molecular Medicine in Berlin. The topic of the thesis was "In vitro differentiation of mouse embryonic stem cells to hepatocyte-like cells".

Maxine has since then worked at a small CRO as a research associate for two years. In 2014, Maxine joined CELLphenomics as one of the first employees. From 2016 to 2018, in addition to working at CELLphenomics, Maxine studied Master of Business Administration with a focus on BioMedTech at the University of Potsdam. Since then she turned her professional focus from lab work more and more to the management part of the company.

Schumacher D, Andrieux G, Boehnke K, Keil M, Silvestri A, Silvestrov M, Keilholz U, Haybaeck J, Erdmann G, Sachse C, Templin M, Hoffmann J, Boerries M, Schäfer R, Regenbrecht CRA. Heterogeneous pathway activation and drug response modelled in colorectal-tumor-derived 3D cultures. PLoS Genetics. 2019 March 29

Schütte M, [...], Silvestrov M, [...], Regenbrecht CRA et al. Molecular dissection of colorectal cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitors. Nat Commun. 2017 Feb 10;8:14262. PubMed PMID: 28186126.

CELL CULTURE & SCREENING EXPERTS

 

Dr. Lena Wedeken

lab manager

MAIL TO

Lena studied human biology at the Philipps-University of Marburg and then joined the group of Professor Karl-Heinz Klempnauer at the Westfälische Wilhelms-University of Münster where she obtained her PhD in biochemistry/molecular biology in 2011. Her PhD research project was focused on the tumor suppressor protein Pdcd4 and its involvement in translational regulation.

Following, Lena moved to Duarte in sunny Southern California for a postdoc at the Beckman Research Institute of City of Hope in the group of Professor Hsun Teresa Ku where she established serum-free culture conditions for primary human and murine adult pancreatic stem- and progenitor-like cells in a 3D culture system and studied the impact of compounds, growth factors, signaling pathways and donor characteristics on these cells.

Before joining CELLphenomics in 2020, Lena was Scientific Officer at the European Association for the Study of Diabetes (EASD) and its associated foundation. Lena has experience in a wide range of cell biology, molecular biology and protein biochemistry methods and techniques and in addition holds a project management certification.

Wedeken L, Luo A, Tremblay JR, Rawson J, Jin L, Gao D, Quijano J, Ku HT (2017). Adult Murine Pancreatic Progenitors Require Epidermal Growth Factor and Nicotinamide for Self-Renewal and Differentiation in a Serum- and Conditioned Medium-Free Culture. Stem Cells Dev. 26:599-607.

Tremblay JR, LeBon J, Luo A, Quijano JC, Wedeken L, Jou K, Riggs AD, Tirrell DA, Ku HT (2016). In vitro Colony Assays for Characterizing Tri-potent Progenitor Cells Isolated from the Adult Murine Pancreas. J Vis Exp 10

Jin L, Gao D, Feng T, Tremblay JR, Ghazalli N, Luo A, Rawson J, Quijano JC, Chai J, Wedeken L, Hsu J, LeBon J, Walker S, Shih HP, Mahdavi A, Tirrell DA, Riggs AD, Ku HT (2015). Cells with Surface Expression of CD133highCD71low are Enriched for Tripotent Colony-Forming Progenitor Cells in the Adult Murine Pancreas. Stem Cell Research 16: 40-53

Wedeken L, Singh P, Klempnauer KH (2011). The Tumor Suppressor Protein Pdcd4 Inhibits the Translation of p53 mRNA. J Biol Chem 286: 42855-62

Singh P, Wedeken L, Waters LC, Carr MD, Klempnauer KH (2011). Proto-oncogene c-myb mRNA is a Direct Target of Tumor Suppressor Protein Pdcd4. Oncogene 30: 4867-73

Wedeken L, Ohnheiser J, Hirschi B, Wethkamp N, Klempnauer KH (2010). Association of Tumor Suppressor Protein Pdcd4 With Ribosomes Is Mediated by Protein-Protein and Protein-RNA Interactions. Genes & Cancer 1: 293-301

Rieck M, Wedeken L, Müller-Brüsselbach S, Meissner W, Müller R (2007). Expression Level and Agonist-Binding Affect the Turnover, Ubiquitination and Complex Formation of Peroxisome Proliferator Activated Receptor Beta. FEBS J 274: 5068-76

Dr. Samantha Exner

project manager

MAIL TO

After a gap year in New Zealand Samantha moved to Greifswald to study human biology. In 2013 she relocated to Berlin joining the group of Carsten Grötzinger in the department of gastroenterology at Charité - Universitätsmedizin Berlin. Since then her research focused on cancer and its targeted diagnosis and therapy. During her PhD Samantha worked on the validation of tumor-specific receptors and the preclinical development of cognate peptide-based ligands. These were optimized in respect of receptor specificity and affinity to act as molecular vehicles transporting contrast agents or therapeutics directly to the site of action. She successfully finished her thesis with the title “G protein-coupled peptide receptors as molecular targets in neuroendocrine tumors”.

Samantha is experienced with in vitro cell based assays as well as imaging and biodistribution analyses using near-infrared or radioactive probes. She worked on the establishment of primary cell cultures and PDX-models of NET origin and applied a wide spectrum of standard methods from molecular biology to protein biochemistry. 

S. Erdmann, L. Niederstadt, E. J. Koziolek, J. D. C. Gómez, S. Prasad, A. Wagener, J. L. v. Hacht, S. Reinicke, S. Exner, S. Bandholtz, N. Beindorff, W. Brenner, C. Grötzinger CMKLR1-targeting peptide tracers for PET/MR imaging of breast cancer Theranostics. 2019 

S. Exner, V. Prasad, B. Wiedenmann, C. Grötzinger Octreotide does not inhibit proliferation in five neuroendocrine tumor cell lines. Front Endocrinol (Lausanne). 2018, PMID: 29681888 

S. Bandholtz, S. Erdmann, J. L. v. Hacht, S. Exner, G. Krause, G. Kleinau, C. Grötzinger Urolinin: The First Linear Peptidic Urotensin-II Receptor Agonist. J Med Chem. 2016, PMID: 27791374 

 

Dr. Jürgen Loskutov

staff scientist

MAIL TO

Before joining the CELLphenomic's team in 2019, Jürgen Loskutov has studied Physiology at Saint Petersburg State University, Russia. In 2010 he joined the group of Professor Elena Pugacheva in West Virginia University, USA, to investigate the role of NEDD9 in breast cancer cell migration and invasion. In 2012 he was accepted into the "Cancer Cell Biology" PhD program at West Virginia University. There under the supervision of Professor Pugacheva he was investigating the association of the primary cilia loss with highly aggressive phenotype in glioblastoma. The aim of his PhD project was to uncover the molecular mechanisms underlaying the increase in proliferation upon loss of primary cilia and to establish if effected pathways can be targeted in glioblastoma. During his PhD he was also strongly involved in establishing new PDXs for WVU HSC PDX Core facility. 

Wright ZC, Loskutov Y, Murphy D, Stoilov P, Pugacheva E, Goldberg AFX, et al. ADP-Ribosylation Factor-Like 2 (ARL2) regulates cilia stability and development of outer segments in rod photoreceptor neurons. Scientific Reports. 2018 Nov 16;8(1):16967.

Loskutov YV, Griffin CL, Marinak KM, Bobko A, Margaryan NV, Geldenhuys WJ, et al. LPA signaling is regulated through the primary cilium: a novel target in glioblastoma. Oncogene. 2018 Mar;37(11):1457.

Jones BC, Kelley LC, Loskutov YV, Marinak KM, Kozyreva VK, Smolkin MB, et al. Dual Targeting of Mesenchymal and Amoeboid Motility Hinders Metastatic Behavior. Mol Cancer Res [Internet]. 2017 Feb 24 [cited 2018 Dec 3]; Available from: mcr.aacrjournals.org/content/early/2017/04/25/1541-7786.MCR-16-0411

Kozyreva VK, Kiseleva A, Ice RJ, Jones BC, Loskutov YV, Matalkah F, et al. Combination of Eribulin and Aurora A inhibitor MLN8237 prevents metastatic colonization and induces cytotoxic autophagy in breast cancer. Mol Cancer Ther. 2016 Jan 1;molcanther.0688.2015.

Loskutov YV, Kozyulina PY, Kozyreva VK, Ice RJ, Jones BC, Roston TJ, et al. NEDD9/Arf6-dependent endocytic trafficking of matrix metalloproteinase 14: a novel mechanism for blocking mesenchymal cell invasion and metastasis of breast cancer. Oncogene. 2015 Jul;34(28):3662.

Lin C-C, Sharma SB, Farrugia MK, McLaughlin SL, Ice RJ, Loskutov YV, et al. Kruppel-like factor 4 signals through microRNA-206 to promote tumor initiation and cell survival. Oncogenesis. 2015 Jun;4(6):e155.

Kozyulina PY, Loskutov YV, Kozyreva VK, Rajulapati A, Ice RJ, Jones BC, et al. Prometastatic NEDD9 Regulates Individual Cell Migration via Caveolin-1–Dependent Trafficking of Integrins. Mol Cancer Res. 2015 Mar 1;13(3):423–38.

McLaughlin SL, Ice RJ, Rajulapati A, Kozyulina PY, Livengood RH, Kozyreva VK, Loskutov YV, et al. NEDD9 Depletion Leads to MMP14 Inactivation by TIMP2 and Prevents Invasion and Metastasis. Mol Cancer Res. 2014 Jan 1;12(1):69–81.

Perekrest SV, Shainidze KZ, Loskutov YV, Abramova TV, Novikova NS, Korneva EA. Immunoreactivity of Orexin-Containing Business in the Hypothalamus and the Level of Expression of the Preproorexin Gene in These Cells after Administration of Lipopolysaccharide. Neurosci Behav Physi. 2013 Feb 1;43(2):256–60.

Plotnikova OV, Nikonova AS, Loskutov YV, Kozyulina PY, Pugacheva EN, Golemis EA. Calmodulin activation of Aurora-A kinase (AURKA) is required during ciliary disassembly and in mitosis. Molecular Biology of the Cell. 2012 Jul 15;23(14):2658.

 

Dr. Katja H Glomm, PhD

screening expert

MAIL TO

Katja Herrera Glomm studied Biotechnology at the TU Berlin and graduated as Dipl. Ing. in 2003 . In the same year she started her PhD at the Leibniz Institute of molecular pharmacology (FMP) in the group of Dr. Enno Klußmann in the field of anchored signaling. The title of her thesis was “Interaction of A-Kinase Anchoring Protein 18 Delta in the Heart and in the Kidney”, and the work involved protein biochemistry as well as immunofluorescence techniques in primary rat renal inner medullary collecting duct and embryonic mouse cardiomyocyte cells. From 2007 until July 2019, she worked at Algenol Biotech Germany in the cyanobacterial research. Katja was member of different groups from cell culture to large-scale cultivation, analytics and down-stream processing.

Lygren B, Carlson CR, Santamaria K, Lissandron V, McSorley T, Litzenberg J, Lorenz D, Wiesner B, Rosenthal W, Zaccolo M, Taskén K, Klussmann E. AKAP complex regulates Ca2+ re-uptake into heart sarcoplasmic reticulum. EMBO Rep. 2007 Nov;8(11):1061-7. Epub 2007 Sep 28.

Nedvetsky PI, Stefan E, Frische S, Santamaria K, Wiesner B, Valenti G, Hammer JA 3rd, Nielsen S, Goldenring JR, Rosenthal W, Klussmann E. A Role of myosin Vb and Rab11-FIP2 in the aquaporin-2 shuttle. Traffic. 2007 Feb;8(2):110-23. Epub 2006 Dec 6.

Stefan E, Wiesner B, Baillie GS, Mollajew R, Henn V, Lorenz D, Furkert J, Santamaria K, Nedvetsky P, Hundsrucker C, Beyermann M, Krause E, Pohl P, Gall I, MacIntyre AN, Bachmann S, Houslay MD, Rosenthal W, Klussmann E.Compartmentalization of cAMP-dependent signaling by phosphodiesterase-4D is involved in the regulation of vasopressin-mediated water reabsorption in renal principal cells.  J Am Soc Nephrol. 2007 Jan;18(1):199-212. Epub 2006 Nov 29.

 

Alina Braukmann, MSc

screening expert

MAIL TO

CURRICULUM VITÆ

Before joining CELLphenomics in 2019, Alina has studied biology and anthropology at the Johannes Gutenberg-University in Mainz, Germany. In 2015, she earned her bachelor’s degree in biology at the Institute of Human Genetics at the Johannes Gutenberg University medical centre in Jennifer Winter's group. The aim of her bachelor thesis The Establishment of P19 Cells as a Neuronal Cell Model was to test and evaluate approaches for the differentiation of the embryonic carcinoma cell line P19. She compared these approaches in terms of practicability, efficiency and reproducibility resulting in a best-practice approach, which is since used as a SOP in her former group. In 2018, she earned her master’s degree in anthropology at the Institute of Pathology at the Johannes Gutenberg University medical centre in the group of Dr. Nils Hartmann. Here, she investigated mitochondrial DNA alterations of colorectal cancer from FFPE tissues by establishing and optimizing an automated NGS screening workflow for sequencing the entire mitochondrial genome.

PUBLICATIONS

visit back shortly

PhD, MD & MASTER STUDENTS

 

Ulrike Pfohl, MSc

PhD candidate

MAIL TO

Ulrike Pfohl finished her apprenticeship as Biology Laboratory Technician at Charité University Medicine Berlin before she started an internship in the genome biology group of Dr. Thomas Caspari in the School of Biological Sciences at Bangor University (UK). Here, she constructed mutant alleles of the S.pombe rad9 DNA damage checkpoint gene. 

Ulrike studied human biology at Ernst-Moritz-Arndt-University in Greifswald. She finished her Bachelor of Science in the field of pediatric oncology, in particular, she investigated the efficacy of a novel hydrolytic-activated prodrug of etoposide (ProVP-16 I) in neuroblastoma cells. Since 2016, she has a master’s degree in human biology. The aim of her master thesis was the analysis of murine stroma components in patient-derived xenograft (PDX) models of pancreatic cancer which she accomplished at EPO - experimental pharmacology & oncology Berlin-Buch GmbH in the group of Dr. Iduna Fichtner. In 2017, she started with her PhD thesis in the same company but now has moved on to pursue her research goals at the Department for Pathology at Otto-von-Guericke University in Magdeburg in cooperation with CELLPHENOMICS GmbH. She is generating CRISPR-engineered organoids of colorectal cancer to utilize them as in vitro models to investigate the effect of specific mutations on drug response.  

Janes S, Schmidt U, Ashour Garrido K, Ney N, Concilio S, Zekri M, Caspari T. Heat induction of a novel Rad9 variant from a cryptic translation initiation site reduces mitotic commitment. J Cell Sci 2012 125: 4487-4497

Lin SJ1, Wardlaw CP, Morishita T, Miyabe I, Chahwan C, Caspari T, Schmidt U, Carr AM, Garcia V. The Rad4(TopBP1) ATR-activation domain functions in G1/S phase in a chromatin-dependent manner. PLoS Genet. 2012 Jun; 8(6)

 

Manuela Regenbrecht

MD candidate

MAIL TO

Manuela studied human medicine at the Charité University Medicine in Berlin. She received her license to practice medicine in November 2014. Since 2015 she is working as a physician in the department of oncology and palliative care at the Helios Klinikum Berlin-Buch. Due to the sarcoma specialization of the department she had the opportunity to work in large part with patients suffering from sarcoma during her medical specialist training.

Since January 2018 Manuela acts as a Clinical Study Manager and MD candidate working on the establishment of patient-derived 3D cell cultures of sarcomas within the framework of the SarQma Study.

Gambara G, Gaebler M, Keilholz U, Regenbrecht CRA, Silvestri A. From Chemotherapy to Combined Targeted Therapeutics: In Vitro and In Vivo Models to Decipher Intra-tumor Heterogeneity. Front Pharmacy. 2018, PMID: 29491834

Gaebler M, Silvestri A, Haybaeck J, Reichardt P, Lowery CD, Stancato LF, Zybarth G, Regenbrecht CRA. Three-Dimensional Patient-Derived In Vitro Sarcoma Models: Promising Tools for improving Clinical Tumor Management. Front Oncol. 2017, PMID: 28955656

Co-Founder

Prof. Dr. Reinhold Schäfer

shareholder

MAIL TO

Reinhold studied biology at Rheinische Friedrich-Wilhelms-University in Bonn. He received a PhD in biology in 1976. He did postdoctoral work at the Max-Planck-Institute of Experimental Medicine in Göttingen and at the Institute of Cell Biology (Tumor Research), the West German Cancer Center, University Hospital Essen. He became staff scientist and group leader at the Ludwig Institute for Cancer Research in Berne, Switzerland, in 1985 and was appointed head of the Division of Cancer Research, Department of Pathology, University of Zürich in 1988. He worked as Professor of Molecular Tumor Pathology at Charité Universitätsmedizin Berlin from 1996-2016. He coordinated the Berlin site within the German Cancer Consortium (DKTK) from 2012-2016. Currently, he is deputy director of the Charité Comprehensive Cancer Center and is working as researcher and advisor within the DKTK and fellow at the German Cancer Research Center (DKFZ) in Heidelberg.

Schumacher D, Andrieux G, Boehnke K, Keil M, Silvestri A, Silvestrov M, Keilholz U, Haybaeck J, Erdmann G, Sachse C, Templin M, Hoffmann J, Boerries M, Schäfer R, Regenbrecht CRA. Heterogeneous pathway activation and drug response modelled in colorectal-tumor-derived 3D cultures. PLoS Genetics. 2019 March 29

Schütte M, Risch T, Abdavi-Azar N, Boehnke K, Schumacher D, Keil M, Yildiriman R, Jandrasits C, Borodina T, Amstislavskiy V, Worth CL, Schweiger C, Liebs S, Lange M, Warnatz HJ, Butcher LM, Barrett JE, Sultan M, Wierling C, Golob-Schwarzl N, Lax S, Uranitsch S, Becker M, Welte Y, Regan JL, Silvestrov M, Kehler I, Fusi A, Kessler T, Herwig R, Landegren U, Wienke D, Nilsson M, Velasco JA, Garin-Chesa P, Reinhard C, Beck S, Schäfer R, Regenbrecht CR, Henderson D, Lange B, Haybaeck J, Keilholz U, Hoffmann J, Lehrach H, Yaspo ML. Molecular dissection of colorectal cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitors. Nat Commun. 8:14262. doi: 10.1038/ncomms14262

Mamlouk S, Childs LH, Aust D, Heim D, Melching F, Oliveira C, Wolf T, Durek P, Schumacher D, Bläker H, von Winterfeld M, Gastl B, Möhr K, Menne A, Zeugner S, Redmer T, Lenze D, Tierling S, Möbs M, Weichert W, Folprecht G, Blanc E, Beule D, Schäfer R, Morkel M, Klauschen F, Leser U, Sers C. DNA copy number changes define spatial patterns of heterogeneity in colorectal cancer. Nat Commun. 8: 14093. doi: 10.1038/ncomms14093

Redmer T, Walz I, Klinger B, Khouja S, Welte Y, Schäfer R, Regenbrecht C. The role of the cancer stem cell marker CD271 in DNA damage response and drug resistance of melanoma cells. Oncogenesis. 23;6(1):e291. doi: 10.1038/oncsis.2016.88.

Boehnke K, Iversen PW, Schumacher D, Lallena MJ, Haro R, Amat J, Haybaeck J, Liebs S, Lange M, Schäfer R, Regenbrecht CR, Reinhard C, Velasco JA. Assay Establishment and Validation of a High-Throughput Screening Platform for Three-Dimensional Patient-Derived Colon Cancer Organoid Cultures. J Biomol Screen. 21(9):931-41. doi: 10.1177/1087057116650965.

Rohr I, Braicu E, En-Nia A, Heinrich M, Richter R, Chekerov R, Dechend R, Heidecke H, Dragun D, Schäfer R, Gorny X, Lindquist JA, Brandt S, Sehouli J, Mertens PR. Y-box protein-1/p18 as novel serum marker for ovarian cancer diagnosis: A study by the Tumor Bank Ovarian Cancer (TOC). Cytokine. 85:157-64. doi: 10.1016/j.cyto.2016.06.021. 

Roßner F, Gieseler C, Morkel M, Royer H-D, Rivera M, Bläker H, Dietel M, Schäfer R, and Sers C. Uncoupling of EGFR-RAS signaling and nuclear localization of YBX1 in colorectal cancer. Oncogenesis, accepted

Győrffy B, Stelniec-Klotz I, Sigler C, Kasack K, Redmer T, Qian, Y and Schäfer R. Effects of RAL signal transduction in KRAS- and BRAF-mutated cells and prognostic potential of the RAL signature in colorectal cancer. Oncotarget, 30;6(15):13334-46.

Relógio A, Thomas P, Medina-Pérez P, Reischl S, Bervoets S, Gloc E, Riemer P, Mang-Fatehi S, Maier B, Schäfer R, Leser U, Herzel H, Kramer A, Sers C. Ras-mediated deregulation of the circadian clock in cancer. PLoS Genet. 29;10(5):e1004338. 

Riemer P, Sreekumar A, Reinke S, Rad R, Schäfer R, Sers C, Bläker H, Herrmann BG, Morkel M. Transgenic expression of oncogenic BRAF induces loss of stem cells in the mouse intestine, which is antagonized by β-catenin activity. Oncogene, 34(24):3164-75

Redmer T, Welte Y, Behrens D, Fichtner I, Przybilla D, Yaspo ML, Lehrach H, Schäfer R and Regenbrecht CRA. The Nerve Growth Factor Receptor CD271 is Crucial to Maintain Tumorigenicity and Stem-Like Properties of Melanoma Cells.  PLoS One 9(5): e92596.

Klinger B, Sieber A, Fritsche-Guenther R, Witzel F, Berry L, Schumacher D, Yan Y, Durek P, Merchant M, Schäfer R, Sers C, Blüthgen N. Network quantification of EGFR signaling unveils potential for targeted combination therapy. Mol Syst Biol. 9:673. 

Penzvaltó Z, Tegze B, Szász AM. Sztupinszki Z, 1, Likó I, Szendröi A, Schäfer R, and Györffy B. Identifying resistance mechanisms against five tyrosine kinase inhibitors targeting the ERBB/RAS pathway in 45 cancer cell lines. PLoS One 8, e59503.

Malek A, Györffy B, Catapano CV and Schäfer R. Selection of optimal combinations of target genes for therapeutic multi-gene silencing based on miRNA co-regulation. Cancer Gene Therapy 20(5):326-9

Welte Y, Davies C, Schäfer R, Regenbrecht CRA. Patient derived cell culture and isolation of CD133+ putative cancer stem cells from melanoma. J. Vis. Exp. e50200, doi:10.3791/50200.

Stelniec-Klotz I, Legewie S, Tchernitsa O, Witzel F, Klinger B, Sers C, Herzel H, Bluthgen N, Schäfer R. Reverse engineering a hierarchical regulatory network downstream of oncogenic KRAS. Mol Syst Biol 8:601. 

Gyorffy B, Benke Z, Lanczky A, Balazs B, Szallasi Z, Timar J, Schäfer R. RecurrenceOnline: an online analysis tool to determine breast cancer recurrence and hormone receptor status using microarray data. Breast Cancer Res Treat 132: 1025-1034

Schäfer R and Sers C. RAS oncogene-mediated deregulation of the transcriptome: From molecular signature to function. Adv. Enzyme Reg. 51: 126-136.

ALUMNI

  • Dr. Yvonne Welte
  • Daniel Bauer, MSc
  • Marco Lee